MHP
VNDA icon

Manatuck Hill Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Manatuck Hill Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-288,000
Closed -$3.15M – 107
2013
Q3 		$3.15M Buy
+288,000
New +$3.08M 0.41% 54

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manatuck Hill Partners's VNDA Position: Q4 2013 in Review

Manatuck Hill Partners sold out of Vanda Pharmaceuticals (VNDA) in Q4 2013, closing a stake of 288,000 shares — an estimated $3.15M sold.

Manatuck Hill Partners first reported a position in VNDA in Q3 2013 and held it in 1 quarter. The position peaked at $3.15M in Q3 2013. 86 funds tracked by Wall St. Rank hold VNDA as of Q4 2013.

  • Manatuck Hill Partners reported no remaining Vanda Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Manatuck Hill Partners sold 288,000 Vanda Pharmaceuticals shares in Q4 2013, an estimated $3.15M.
  • Manatuck Hill Partners first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Manatuck Hill Partners's Vanda Pharmaceuticals position peaked at $3.15M in Q3 2013.
  • 86 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2013.

Based on Manatuck Hill Partners's 13F filing for Q4 2013, filed 14 Feb 2014.